News | January 09, 2015

FDA Clears Version 1.2 of Dune Medical’s MarginProbe

Real-time breast cancer-detection device update offers brighter screen, reduced size and emphasized alerts

Dune Medical Devices, MarginProbe, version 1.2, FDA, breast cancer detection

Image courtesy of Dune Medical Devices

January 9, 2015 — Dune Medical Devices announced U.S. Food and Drug Administration (FDA) approval of an updated version of its flagship product, MarginProbe, a medical device that enables real-time detection of cancer at the surface of excised tissue specimens during breast-conserving cancer surgery.

Surgeon feedback, innovative design ideas and superior miniaturization engineering were the driving forces behind the development of MarginProbe 1.2. This new version, which utilizes the same FDA-approved diagnostic technology as version 1.1, is focused on providing superior functionality, portability and overall ease of use.

Feature enhancements for MarginProbe 1.2 include:

  • Reduced size & weight: The new unit is in tabletop form (29 x 43 x 38 cm in size) and weighs 35 lbs. making it 75-percent lighter and much easier to handle.
  • Brighter screen: The screen’s brightness has been enhanced to provide surgeons a clearer screen image.
  • Wider viewing angle: With MarginProbe 1.2, surgeons will have the ability to clearly view the screen from anywhere in the operating room without encountering a glare, pixelation or a blind spot.
  • Improved on-screen notices: Ensuring key alerts are easier to notice in the OR ambience.
  • Startup time cut in half: The startup time for MarginProbe 1.2 is reduced from approximately three minutes to 90 seconds.
  • Improved service time: Due to its new reduced size, technicians are able to provide faster service, reducing down time in case service is needed.

For more information: www.dunemedical.com

Related Content

California Women In Favor of Extending State's Breast Density Inform Law
News | Breast Density | June 15, 2018
A recent survey of California women found that 95 percent of respondents want the state’s breast density inform law to...
Women More Likely to Use Other Preventive Health Services Following Mammography
News | Mammography | June 13, 2018
Medicare beneficiaries who undergo breast cancer screening with mammography are more likely than unscreened women to...
How AI and Deep Learning Will Enable Cancer Diagnosis Via Ultrasound

The red outline shows the manually segmented boundary of a carcinoma, while the deep learning-predicted boundaries are shown in blue, green and cyan. Copyright 2018 Kumar et al. under Creative Commons Attribution License.

News | Ultrasound Imaging | June 12, 2018 | Tony Kontzer
June 12, 2018 — Viksit Kumar didn’t know his mother had...
Breast imaging technologies have seen a rapid evolution.

Breast imaging technologies have seen a rapid evolution.

Feature | Women's Health | June 05, 2018 | By Jeff Zagoudis
Breast imaging technologies have evolved rapidly in the last two decades to help physicians detect breast cancers at
Breast Cancer Survivors Not Getting Recommended Number of Mammograms Post-Surgery
News | Mammography | May 24, 2018
Breast cancer survivors are not getting the recommended level of screening post-surgery, according to a newly-published...
Breast Cancer Places Greater Financial Burden on Black Women
News | Women's Health | May 16, 2018
Having breast cancer placed a significantly greater financial strain on black women than white women, according to a...
FDA's MQSA Accreditation Bodies Approved for Tomosynthesis Accreditation

Image courtesy of Fujifilm.

Feature | Mammography | May 14, 2018
On April 9, 2018, the U.S. Food and Drug Administration (FDA) announced that all four of its Mammography Quality...
Overlay Init